logo-loader

Scancell's melanoma vaccine wins FDA designation as phase III trial nears

Published: 18:06 19 Nov 2026 AEDT

Scancell Holdings PLC - Scancell's melanoma vaccine wins FDA designation as phase III trial nears

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), the cancer immunotherapy developer, has won Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its lead melanoma treatment.

The drug, inzitagene plasmivec (iSCIB1+), is a DNA vaccine designed to train the immune system's T cells to attack skin cancer.

RMAT carries the benefits of the FDA's Fast Track and Breakthrough Therapy schemes, including closer guidance and eligibility for priority review and accelerated approval if criteria are met.

The global phase III trial remains on track to enrol its first patient in December.

Updated phase II SCOPE data, with the vaccine given alongside checkpoint inhibitors (drugs that release the brakes on the immune system), show overall survival of 82% at 24 months across 80 patients.

The iSCIB1+ group alone reached 87%.

Progression-free survival, the time patients live without their cancer worsening, was 71% at 24 months for iSCIB1+ in the target HLA population, against 41.5% for standard ipilimumab and nivolumab treatment in the earlier CheckMate 067 study.

The complete response rate has improved to 28% across both cohorts, and 31% in the latest iSCIB1+ cohort.

Scancell also reported results from its Phase 2 ModiFY trial of Modi-1, a different vaccine, in kidney cancer.

Among 43 patients given Modi-1 with ipilimumab and nivolumab, the objective response rate (the share whose tumours shrank) was 48% and median progression-free survival was 7.8 months.

Some 46% developed a vaccine-specific immune response, and these patients fared better, with six-month progression-free survival of 75% against 50% for non-responders.

In head and neck cancer, responders had median progression-free survival of 4.5 months against 2 months, a difference that was not statistically significant.

Scancell remains on course to complete a Nasdaq listing in late 2026 or early 2027 through a merger with Neuphoria Therapeutics, which would fund the Phase 3 trial.

Phillip L'Huillier, chief executive, said the RMAT designation "recognises its potential to address an unmet need in advanced melanoma".

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates. A placing and subscription at 12 pence a share will account for...

on 18/4/18